Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patient

• 作 者: Katherine Kutney Shannon B Don
• 机 构: DepartmentofPediatricEndocrinology,DepartmentofPediatrics,DepartmentofRadiologyCaseWesternReserveUni
• 出 处: 世界肝病学杂志:英文版(电子版)
• 发表日期: 2019年12期
• 关键词: CYSTIC FIBROSIS LIVER disease Non-alcoholic fatty LIVER disease CYSTIC FIBROSIS
• 基金项目: Supported by a grant from the University Hospitals Fellowship Research Award Program(FRAP).

BACKGROUND Hepatic steatosis is a common form of cystic fibrosis associated liver disease(CFLD)seen in an estimated 15%-60%of patients with cystic fibrosis(CF).The pathophysiology and health implications of hepatic steatosis in cystic fibrosis remain larg